Skip to main content

Advertisement

SpringerLink
Log in

The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The poor prognosis of chronic lymphocytic leukemia (CLL) patients with del(17p13) is well established. Several studies have shown that cases with TP53 mutations and TP53 mutations without del(17p13) may be adverse prognostic factors. We studied 173 well-characterized CLL patients by direct sequencing to detect TP53 mutations (exons 2–11). TP53 mutations were detected in 14.5% (25 of 173) of samples. Most patients with del(17p13) had TP53 mutations (72.2%). Mutations in the absence of del(17p13) were found in 8.3% in our cohort, which were higher than other countries. Compared with cases without TP53 alterations, TP53 mutations and deletions were both associated with advanced stages and unmutated immunoglobulin heavy-chain variable region status. Survival analysis showed that the occurrence of TP53 mutations and del(17p13) were associated with shorter overall survival (OS), treatment-free survival (TFS), and resistance to chemotherapy. TP53 mutations were the variables strongly associated with OS and TFS by multivariate Cox regression analysis. Moreover, we also found that cases with TP53 mutations in the absence of del(17p13) had a similar clinical and biological course and similar poor short OS as cases carrying del(17p13) in Chinese patients with CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Xu W, Li JY, Wu YJ et al (2008) Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1071–1077

    Article  PubMed  CAS  Google Scholar 

  2. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815

    Article  PubMed  CAS  Google Scholar 

  3. Berkova A, Pavlistova L, Babicka L et al (2008) Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia. Neoplasma 55:400–408

    PubMed  CAS  Google Scholar 

  4. Lin K, Sherrington PD, Dennis M et al (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404–1409

    Article  PubMed  CAS  Google Scholar 

  5. Pettitt AR, Sherrington PD, Stewart G et al (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 98:814–822

    Article  PubMed  CAS  Google Scholar 

  6. Rossi D, Cerri M, Deambrogi C et al (2009) The prognosis value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13. Clin Cancer Res 15:995–1004

    Article  PubMed  CAS  Google Scholar 

  7. Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278–3281

    Article  PubMed  CAS  Google Scholar 

  8. Krober A, Bloehdorn J, Hafner S et al (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969–975

    Article  PubMed  Google Scholar 

  9. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood 111:5446–5456

    Article  PubMed  CAS  Google Scholar 

  10. Dicker F, Herholz H, Schnittger S et al (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117–124

    Article  PubMed  CAS  Google Scholar 

  11. Zenz T, Habe S, Denzel T et al (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53–p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589–2597

    PubMed  CAS  Google Scholar 

  12. Zenz T, Eichhorst B, Busch R et al (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473–4479

    Article  PubMed  Google Scholar 

  13. Mayr C, Speicher MR, Kofler DM et al (2006) Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107:742–751

    Article  PubMed  CAS  Google Scholar 

  14. Thornton PD, Gruszka-Westwood AM, Hamoudi RA et al (2004) Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 5:47–54

    Article  PubMed  CAS  Google Scholar 

  15. Grever MR, Lucas DM, Dewald GW et al (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799–804

    Article  PubMed  CAS  Google Scholar 

  16. Zenz T, Krober A, Scherer K et al (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112:3322–3329

    Article  PubMed  CAS  Google Scholar 

  17. Grever MR, Lucas DM, Johnson AJ, Byrd JC (2007) Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20:545–556

    Article  PubMed  CAS  Google Scholar 

  18. Best OG, Gardiner AC, Majid A et al (2008) A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 22:1456–1459

    Article  PubMed  CAS  Google Scholar 

  19. Sturm I, Bosanquet AG, Hermann S et al (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477–484

    Article  PubMed  CAS  Google Scholar 

  20. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629

    Article  PubMed  CAS  Google Scholar 

  21. Soussi T, Asselain B, Hamroun D et al (2006) Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12:62–69

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by National Natural Science Foundation of China (30871104, 30971295, 30971296), Jiangsu Province’s Outstanding Medical Academic Leader Program (LJ200623), Jiangsu Province’s Medical Elite Program (RC2007042), and National Science and Technology Pillar Program (2008BAI61B01).

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China

    Hua-Jie Dong, Li-Tao Zhou, Dan-Xia Zhu, Dong-Mei Wang, Cheng Fang, Hua-Yuan Zhu, Yun Zhuang, Kou-Rong Miao, Wei Xu & Jian-Yong Li

Authors
  1. Hua-Jie Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li-Tao Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan-Xia Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dong-Mei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hua-Yuan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yun Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kou-Rong Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jian-Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Xu or Jian-Yong Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dong, HJ., Zhou, LT., Zhu, DX. et al. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol 90, 709–717 (2011). https://doi.org/10.1007/s00277-010-1125-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1125-8

Keywords

Search

Navigation